Clinical trials: Hyperphosphatemia Patients on Peritoneal Dialysis
Hyperphosphatemia
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
- Trial name
- NCT01518387
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 11 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Bayer
Hyperphosphatemia
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control.
- Trial name
- NCT00508885
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Chronic Renal Failure
Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01903213
- Testing
- bixalomer
- Where
- 8 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals
Hyperphosphatemia Patients on Peritoneal Dialysis
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis
- Trial name
- NCT07548853
- Testing
- 'TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Peritoneal Dialysis Complication, Hyperphosphatemia
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.
- Conditions
- Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
- Trial name
- NCT04046263
- Testing
- Sucroferric Oxyhydroxide Chewable Tablet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Hyperphosphatemia
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and…
- Trial name
- NCT04766385
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (PD) Patients
Hyperphosphatemia is highly prevalent in PD patients, and it is an independent risk factor for all-cause and cardiovascular mortality in these patients. Effective treatments are limited in suppressing plasma phosphorous.
- Trial name
- NCT01329497
- Testing
- systemic dietary instruction
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Kidney Disease, Renal Dialysis
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 in chronic kidney disease and hyperphosphatemia patients on peritoneal dialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency
- Trial name
- NCT01017276
- Testing
- ASP1585
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Inc